Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Innovent/AnHeart File China NDA for ROS1 Inhibitor to Treat NSCLC

publication date: Mar 5, 2024

Suzhou Innovent and AnHeart Therapeutics of Hangzhou have filed a second NDA of their partnered next-gen ROS1 TKI in China. The new NDA, which has been accepted for review by China’s CDE, is for use of taletrectinib as a first-line therapy for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have not previously been treated with a ROS1 TKI. The first NDA filing was for NSCLC patients who have been previously treated with ROS1 TKIs. In 2021, Innovent entered a $189 million agreement with AnHeart to commercialize taletrectinib in Greater China. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here